Jade reports interim Phase I results of JADE101 for IgAN

​Jade Biosciences has reported positive interim data from its Phase I trial studying JADE101, an investigational anti-APRIL monoclonal antibody for IgAN.

The post Jade reports interim Phase I results of JADE101 for IgAN appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

MicroPort launches LBBOT Solution commercially in Europe and Australia
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
SKIA secures FDA 510(k) clearance for AR surgical platform
FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy
Labcorp announces partnership for colorectal cancer trials

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us